Clinical trials: Advanced Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma (NPC)
Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
The main questions it aims to answer are: 1. Does the combination of GP induction chemotherapy and toripalimab improve the 3-year progression-free survival (PFS) compared to GP induction chemotherapy with placebo? 2.
- Trial name
- Navigation (NCT06712888)
- Testing
- TORIPALIMAB INJECTION (JS001 ) combine with GP chemotherapy
- Where
- 10 sites in China
- Volunteers
- 466 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With LA-NPC
Nasopharyngeal carcinoma (NPC) is a malignant tumor that originates in nasopharyngeal epithelial cells. It is common in southern China and Southeast Asia, but the incidence rate is low in most parts of the world.
- Trial name
- NCT04015661
- Testing
- Nab-paclitaxel
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Fuzhou General Hospital
Advanced Nasopharyngeal Carcinoma
SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC
Radiotherapy and immunotherapy have achieved good survival benefit in advanced nasopharyngeal carcinoma. A number of clinical studies of immunotherapy combined with radiotherapy for nasopharyngeal carcinoma are also ongoing.
- Trial name
- NCT05652192
- Testing
- SBRT
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Zhejiang Cancer Hospital
Head and Neck Cancer
Docetaxel and S-1 Followed By Radiation Therapy and Low-Dose Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, S-1, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00625937
- Testing
- cisplatin, docetaxel, tegafur-gimeracil-oteracil potassium
- Where
- South Korea
- Volunteers
- 46 people
- Sponsor
- Yonsei University
Head and Neck Cancer
Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
RATIONALE: Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This phase I trial is studying the side effects of stereotactic radiosurgery in treating…
- Trial name
- NCT00851253
- Testing
- stereotactic radiosurgery
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Boston Medical Center
Nasopharyngeal Carcinoma
Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to compare induction chemotherapy (TPF or GP) plus radiotherapy alone with induction chemotherapy plus concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma…
- Trial name
- NCT04414566
- Testing
- gemcitabine and cisplatin; docetaxel, cisplatin and fluorouracil, IMRT, IMRT and concurrent cisplatin
- Where
- China
- Volunteers
- 562 people
- Sponsor
- West China Hospital
Nasopharyngeal Cancinoma (NPC)
GP Combined with Toripalimab Versus GP Induction Chemotherapy for Advanced Childhood Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) has a low incidence rate in children, accounting for only 1-2% of pediatric tumors. However, it is prone to metastasis, and most patients are already in advanced stages at the time of diagnosis.
- Trial name
- NCT06605131
- Testing
- GP+Toripalimab+CCRT, GP+CCRT
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Sun Yat-sen University
Esophageal Neoplasms
Chronomodulated Chemotherapy Followed by Concurrent Chemo-radiotherapy With IMRT in the Treatment of Advanced Nasopharyngeal Cancer
1. Observe and compare the chrono-chemotherapy IMRT and conventional chemotherapy and intensity modulated radiotherapy term efficacy of the treatment of locally advanced nasopharyngeal carcinoma. 2.
- Trial name
- NCT02937519
- Testing
- Chrono-chemotherapy pump:Melodie, Routine intravenous drip, induction Chrono-chemotherapy
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Guiyang Medical University
Nasopharyngeal Carcinoma, Sintilimab
Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
The program aims to enroll patients with stage high risk (AJCC 8th, T3-4N2-3M0) . Patients will receive 3 cycles of induction chemotherapy with gemcitabine and cisplatin and concurrent cisplatin-radiation plus Sintilimab, and…
- Trial name
- NCT05707819
- Testing
- Sintilimab (PD-1 Antibody)
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Cancer Hospital of Guangxi Medical University
Head and Neck Cancer
Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether methotrexate or paclitaxel is more effective in treating patients with advanced…
- Trial name
- NCT00003592
- Testing
- methotrexate, paclitaxel
- Where
- 20 sites in United States, South Africa
- Volunteers
- 230 people
- Sponsor
- Eastern Cooperative Oncology Group
Nasopharyngeal Carcinoma
TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
The NCCN guidelines recommend induction chemotherapy followed by concurrent chemoradiotherapy as the standard treatment for locoregionally advanced nasopharyngeal carcinoma (NPC).
- Trial name
- NCT06301165
- Testing
- TPC induction chemotherapy, GP induction chemotherapy
- Where
- 8 sites in China
- Volunteers
- 162 people
- Sponsor
- Sun Yat-sen University
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Stage III Squamous Cell Carcinoma of the Hypopharynx
Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity
- Trial name
- NCT00049283
- Testing
- erlotinib hydrochloride, docetaxel, radiation therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Nuclear Medicine, Oncology
Application of 18F-FDG PET/MRI for Initial Staging in Locally Advanced Nasopharyngeal Carcinoma
This single-center prospective observational study aims to evaluate the feasibility, cost-effectiveness, and clinical value of positron emission tomography/magnetic resonance imaging (PET/MRI) for initial staging in patients with…
- Trial name
- NCT06947759
- Testing
- PET/MRI
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- Taichung Veterans General Hospital
Esophageal Cancer, Extrahepatic Bile Duct Cancer
Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gastric Cancer, Head and Neck Cancer
- Trial name
- NCT00021047
- Testing
- capecitabine, carboplatin, epirubicin hydrochloride
- Where
- 3 sites in United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Colorectal Cancer, Renal Cell Carcinoma
Study of DC-CTL Combined With CIK for Advanced Solid Tumor
Background: Combinations of Dendritic and Cytokine-induced Killer Cells (DC-CIK) and Cytokine-induced Killer Cells (CIK) treatment may enhance the immune response and stop cancer cells from growing.
- Conditions
- Colorectal Cancer, Renal Cell Carcinoma, Nasopharyngeal Carcinoma, Lung Cancer
- Trial name
- NCT03047525
- Testing
- Cytokine-induced Killer Cells
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Xiaoyi Huang
Nasopharyngeal Cancer
Docetaxal & Cisplatin vs LDFRT + Docetaxal & Cisplatin in Locally Advanced NPC
The central hypothesis is to test Low Dose Fraction Radiotherapy (LDFRT), as a potentiator of Docetaxel and Cisplatin efficacy in locally advanced nasopharyngeal cancer.
- Trial name
- NCT03890185
- Testing
- Chemo + Low dose RT, Chemo alone
- Volunteers
- 108 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Metastatic Tumor, Advanced Solid Tumor
A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors
This is a single-center, single-arm ，open-label ，dose escalation and dose extension study. In this study we plan to evaluate the safety and efficacy of CD70-targeting UCAR-T cells in the treatment of CD70-positive refractory or…
- Conditions
- Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer
- Trial name
- NCT06383507
- Testing
- CHT101
- Volunteers
- 18 people
- Sponsor
- Zhejiang University
Nasopharyngeal Carcinoma (NPC)
Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial
This multicenter, open-label, randomized Phase III trial evaluates intensity-modulated proton therapy (IMPT) versus intensity-modulated photon radiotherapy (IMRT) in patients with newly diagnosed, high-risk, locoregionally…
- Trial name
- NCT07340515
- Testing
- Intensity-Modulated Proton Therapy (IMPT), Intensity-Modulated Radiation Therapy (IMRT), Cisplatin
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Man Hu
Nasopharyngeal Neoplasms
Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma
The present study will be a randomized, control, multicenter phase III study of recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) treated with Gemcitabine (Gemzar, Lilly) and cisplatin regimen (GP) or 5-Fluorouracil…
- Trial name
- NCT01528618
- Testing
- gemcitabine and cisplatin, 5-Fluorouracil and cisplatin
- Where
- China
- Volunteers
- 362 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
Neoadjuvant chemotherapy plus toripalimab in patients with locoregionally advanced nasopharyngeal carcinoma
- Trial name
- NCT05813626
- Testing
- Toripalimab, Gemcitabine (GEM), Cisplatin
- Where
- China
- Volunteers
- 89 people
- Sponsor
- Zhejiang Cancer Hospital